News | May 07, 2007

Strategic Relationship Formed to Improve Patient Safety Through Medical Information Innovations

May 8, 2007 - OBS Medical and Physio-Control Inc., a wholly-owned subsidiary of Medtronic Inc., announced they have entered into a strategic relationship to improve patient safety through medical information innovations in external defibrillation monitoring technologies.

Under this global strategic relationship, which was announced by both companies at the 3rd International Conference on Rapid Response Systems, Physio-Control will license OBS Medical's BioSign technology to incorporate it into future monitoring and defibrillation products. The two companies will also collaborate in research for medical algorithms to better manage sudden cardiac arrest.

"We are excited to enter into this strategic relationship with Physio-Control, a pioneer and innovator in the global external defibrillation marketplace," said Frank Cheng, president and CEO of OBS Medical. "This is a major step toward ensuring better patient safety in and outside of hospitals. By integrating the BioSign algorithm with Physio-Control's future defibrillation products, we hope to add significant clinical insights for better assessment of patients' clinical conditions, and enable doctors and nurses to identify and respond to critically ill patients more effectively."

"This new strategic relationship is especially exciting to us as we create monitoring and resuscitation solutions for the future," said Brian Webster, president of Physio-Control. "OBS Medical's technology, the BioSign Index, will provide hospital and other clinicians, such as emergency medical services professionals, with an early warning index enabling them to more quickly respond in urgent medical situations when time is of the essence."

Related Content

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Overlay Init